ClinicalTrials.gg
TerminatedNCT06610279Updated Nov 22, 2024Results posted

A Study of TAK-951 in Healthy Adults

A Phase 1 interventional study of TAK-951 and Placebo in Healthy Volunteers, sponsored by Takeda. Terminated at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated based on the Sponsor's decision attributed to the benefit-risk profile derived from the Part 1 data of this study.

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jan 2022, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Feeling sick in the stomach (nausea) or throwing up (vomiting) are among the most common symptoms during treatment with medicines. It is hoped that a medicine called TAK-951 may help people to not feel sick in the stomach or throw up. The main aim of this study is to learn about side effects of TAK-951 when given as a single or multiple doses to healthy adults. Side effects are medical problems thought to be caused by the study treatment. Another aim is to learn how a healthy adult's body processes TAK-951 (this is called pharmacokinetics or PK). In this study, participants will receive either TAK-951 or placebo. The placebo looks like TAK-951 but does not have any medicine in it. Both TAK-951 and placebo will be given as an injection directly under the skin. This is called subcutaneous or subcutaneous (SC).

The study will be conducted in 3 parts:

  • In Part 1, participants will be given one SC injection of either TAK-951 or placebo.
  • In Part 2, participants will receive up to three daily SC injections of either TAK-951 or placebo of the same dose
  • In Part 3, participants will receive one SC injection of either TAK-951 or placebo and another SC injection up to 1 week later.

Participants will be checked for their health either 28 days after the last injection (Parts 1 and 2) or 14 days after the last injection (Part 3).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • TAK-951
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria

To be eligible for participation in this study, the participant must:

  1. Understand the study procedures and agree to participate by providing written .
  2. Be willing and able to comply with all study procedures and restrictions.
  3. Be a healthy man or woman aged 18 to 55 years, inclusive, at the screening visit.
  4. Be a continuous nonsmoker who has not used nicotine and tobacco-containing products for at least 3 months prior to dosing and throughout the study.
  5. Have a (BMI) greater than equal to (≥)18 and less than equal to (≤)32 kilograms per meter square (kg/m\^2) at the screening visit.
  6. Be judged to be in good health (e.g., no evidence of psychiatric, hepatic, renal, pulmonary, or cardiovascular (CV) disease) by the investigator, based on clinical evaluations including laboratory safety tests, medical history, physical examination, , and vital sign measurements performed at the screening visit and before administration of the initial dose of study drug or invasive procedure.
  7. Meet the following requirements:

    • Is a male participant who is sterile or agrees to use an appropriate method of contraception, including a condom with or without spermicidal cream or jelly, from the first dose of study drug until 30 days after the last dose of study drug. No restrictions are required for a vasectomized male participant provided the participant is at least 1 year after bilateral vasectomy procedure before the first dose of study drug. A male participant whose vasectomy procedure was performed less than 1 year before the first dose of study drug must follow the same restrictions as a non-vasectomized man. Appropriate documentation of surgical procedure should be provided.
    • Is a male participant who agrees not to donate sperm from the first dose of study drug until 30 days after the last dose of study drug.
    • Women of are eligible for the study provided they have a negative pregnancy test, are not lactating or breastfeeding, and are willing and agreeable to use highly effective contraception during the study and up to 30 days after the last dose of study drug.
    • Is a female participant of nonchildbearing potential, defined by at least 1 of the following criteria:

      1. (defined as 12 months of spontaneous amenorrhea in females aged greater than (>)45 years or 6 months of spontaneous amenorrhea in females aged >45 years with serum follicle-stimulating hormone (FSH) levels >40 milli-international units per milliliter [mIU/mL]). Appropriate documentation of FSH levels is required.
      2. Surgically sterile by hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy with appropriate documentation of surgical procedure.
      3. Had a bilateral tubal ligation with appropriate documentation of surgical procedure.
      4. Has a congenital condition resulting in no uterus. Exclusion Criteria

Any participant who meets any of the following criteria will not qualify for entry into the study:

  1. The participant has participated in another study within 4 weeks (or based on local regulations) or within 5 half-lives, whichever is longest, of the investigational product before the screening visit. The 4-week or 5 half-lives window will be derived from the date of the last dose and/or AE related to the study procedure in the previous study to the screening visit of the current study.
  2. The participant is an employee of the sponsor or study site or immediate family member (e.g., spouse, parent, child, sibling) of the sponsor or study site.
  3. The participant has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food, as determined by the investigator.
  4. The participant has a known or to any component of TAK-951.
  5. The participant has a positive pregnancy test or is lactating or breastfeeding.
  6. The participant has a positive test result for surface antigen, virus antibody, or human immunodeficiency antibody/antigen, at the screening visit.
  7. The participant had major surgery or donated or lost 1 unit of blood (approximately 500 milliliters [mL]) within 4 weeks before the screening visit.
  8. The participant is unable to refrain from or anticipates using any medications including herbal medicines beginning approximately 7 days before administration of the first dose of study drug, throughout the study until 2 days after discharge.
  9. The participant is unable to refrain from or anticipates using marijuana or cannabis-containing products beginning approximately 7 days before administration of the first dose of study drug, throughout the study until after the last pharmacokinetic (PK) dose.
  10. The participant has a history or presence of alcoholism or drug abuse within the past 2 years prior to dosing, or frequent or heavy use (i.e., near-daily) of medical or recreational cannabis in the past 3 months before screening, as determined by the investigator.
  11. The participant drinks alcohol in excess of 7 drinks/week for women or 14 drinks/week for men (where 1 drink=5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor [45% alcohol]) within 3 months before screening.
  12. The participant has a positive alcohol test or urine drug screen results at screening or check-in.
  13. The participant has had a previous major psychiatric disorder.
  14. The participant has a history or presence of:

    • 3 or more incidences of vasovagal syncope within the last 5 years prior to screening; or
    • A family history of unexplained sudden death or channelopathy; or
    • Brugada syndrome (i.e., right bundle branch block [RBBB] pattern with ST-elevation in leads V1-V3); or
    • Cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, stroke, sick sinus syndrome, pulmonary congestion, symptomatic or significant cardiac arrhythmia, second-degree atrioventricular (AV) block type 2, third-degree AV block, prolonged with Fridericia correction method (QTcF) interval, hypokalemia, hypomagnesemia, or conduction abnormalities; or
    • Risk factors for Torsade de Pointes (e.g., heart failure, cardiomyopathy, or family history of Long QT Syndrome); or
    • Any ECG findings or medical history including: long or short QTcF (over 450 milliseconds (msec) or less than 360 msec), bifascicular block or QRS ≥120 msec or PR interval >210 msec at screening or Day 1 pre-Hour 0; or
    • The participant has a documented history of sinus bradycardia (\<45 beats per minute [bpm]), sinoatrial block or sinus pause ≥3 seconds.
  15. The participant has an average semirecumbent blood pressure (BP) less than (\<)90/60 millimeters of mercury (mm Hg) or >140/90 mm Hg from screening to predose, inclusive. Any assessments on Day -1 that do not meet this criterion must be discussed with the medical monitor for approval.
  16. The participant has an average semirecumbent heart rate (HR) (pulse) \<55 or >100 bpm at any time point from screening to predose, inclusive. Participants with an average HR (pulse) \<55 bpm can be enrolled only with medical monitor approval. Any assessments after admission with an average HR (pulse) \<55 bpm at any time point, from Day -2 to predose (inclusive), will be left to the judgment of the investigator, unless HR (pulse) is \<50 bpm, which must be discussed with the medical monitor for approval.
  17. The participant has orthostatic hypotension defined as a decrease in systolic blood pressure (SBP) ≥20 mm Hg or a decrease in diastolic blood pressure (DBP) ≥10 mm Hg at approximately 3 minutes of standing when compared with BP from the semirecumbent position at screening to predose assessments, inclusive. In asymptomatic participants, any assessments after screening that do not meet this criterion may be repeated after the participant has remained in the semirecumbent or supine position for 15 minutes. If the repeat assessment is exclusionary based on the above criterion, the participant will not be eligible. If the repeat assessment is not exclusionary, the participant will be eligible.
  18. The participant has postural orthostatic tachycardia, defined as an increase of >30 bpm or pulse >120 bpm at approximately 3 minutes of standing, at screening to predose assessments, inclusive. Any assessments after screening that do not meet this criterion may be repeated with the participant remaining standing for up to a total of 5 minutes, provided that the participant remains asymptomatic. If the repeat assessment occurring within 5 minutes is exclusionary based on the above criterion, the participant will not be eligible. A confirmed orthostatic increase of >30 bpm, but \<40 bpm, on 1 or more Day -1 assessments may not be considered exclusionary if not considered clinically significant by the investigator and the medical monitor. Such assessments must be discussed with the medical monitor before determination that the participant is eligible to proceed.
  19. The participant has a known or suspected current coronavirus disease 2019 (COVID-19) infection or is at risk of COVID-19 infection as assessed by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Placebo comparator
    Part 1: Pooled Placebo

    Participants will receive a single SC dose of TAK-951 matching placebo on Day 1.

    Drug: Placebo

  • Experimental
    Part 1, Cohort 1: TAK-951 Dose 1

    Participants will receive a single SC dose of TAK-951 Dose 1 on Day 1.

    Drug: TAK-951

  • Experimental
    Part 1, Cohort 2: TAK-951 Dose 2

    Participants will receive a single SC dose of TAK-951 Dose 2 on Day 1.

    Drug: TAK-951

  • Experimental
    Part 1, Cohort 3: TAK-951 Dose 3

    Participants will receive a single SC dose of TAK-951 Dose 3 on Day 1.

    Drug: TAK-951

  • Experimental
    Part 1, Cohort 4: TAK-951 Dose 4

    Participants will receive a single SC dose of TAK-951 Dose 4 on Day 1.

    Drug: TAK-951

  • Experimental
    Part 1, Cohort 5: TAK-951 Dose 5

    Participants will receive a single SC dose of TAK-951 Dose 5 on Day 1.

    Drug: TAK-951

  • Experimental
    Part 1, Cohort 6: TAK-951 Dose 6

    Participants will receive a single SC dose of TAK-951 Dose 6 on Day 1.

    Drug: TAK-951

  • Experimental
    Part 2: TAK-951 Multiple Rising Doses

    Participants will receive multiple rising SC doses of TAK-951 twice daily (BID) or 3 times a day (TID) in Part 2.

    Drug: TAK-951

  • Experimental
    Part 3: TAK-951 Multiple Dose Titration

    Participants will receive multiple rising SC doses of TAK-951 once daily (QD), BID, or TID from Days 1 to 5 followed by a washout period of 2 to 7 days and a single redose on any day from Days 8 to 13 in Part 3.

    Drug: TAK-951

Interventions

  • TAK-951 SC injection

  • DrugPlacebo

    TAK-951 matching placebo SC injection

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, electrocardiogram (ECG), laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.

    Time frame: From the first dose of study drug up to Day 29 in Part 1

  2. Part 2: Number of Participants With TEAEs

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.

    Time frame: From the first dose of study drug up to Day 33 in Part 2

  3. Part 3: Number of Participants With TEAEs

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.

    Time frame: From the first dose of study drug up to Day 27 in Part 3

Secondary outcomes

  1. Part 2: Maximum Observed Plasma Concentration (Cmax) for TAK-951 on Day 1 of Drug Dosing

    Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

  2. Part 2: Time of First Occurrence of Cmax (Tmax) for TAK-951 on Day 1 of Drug Dosing

    Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

  3. Part 2: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) for TAK-951 on Day 1 of Drug Dosing

    Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

  4. Part 2: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval for TAK-951 on Day 1

    Tau (τ) indicates the length of the dosing interval.

    Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

  5. Part 2: AUCτ for TAK-951 at Steady State

    τ indicates the length of the dosing interval.

    Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

  6. Part 2: AUC24 for TAK-951 at Steady State

    Time frame: Predose on Day 1 and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

  7. Part 2: Cmax,ss: Maximum Observed Concentration at Steady State for TAK-951

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

  8. Part 2: Tmax for TAK-951 at Steady State

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

  9. Part 2: Terminal Disposition Phase Half-life (t1/2z) for TAK-951 at Steady State

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

  10. Part 2: Apparent Clearance After Extravascular Administration (CL/F) for TAK-951 at Steady State

    Apparent clearance after extravascular administration was to be calculated as Dose/AUCτ after multiple dosing.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

  11. Part 2: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration (Vz/F) for TAK-951 at Steady State

    Apparent volume of distribution during the terminal disposition phase after extravascular administration was to be calculated as (CL/F)/λz at steady state, with λz as the terminal elimination rate constant.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

  12. Part 2: Ctrough: Observed Plasma Concentration at the End of a Dosing Interval for TAK-951 at Steady State

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

  13. Part 2: Rac[AUC]: Accumulation Ratio Based on AUCτ for TAK-951 at Steady State

    Rac\[AUC\] was to be calculated as the ratio of AUCτ at steady state/AUCτ after a single dose.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

  14. Part 2: Rac[Cmax]: Accumulation Ratio Based on Cmax for TAK-951 at Steady State

    Rac\[Cmax\] was to be calculated as the ratio of Cmax at steady state/Cmax after a single dose.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

  15. Part 3: Number of Participants With AEs

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.

    Time frame: From the re-treatment dose of study drug (any day from Days 8 to 13) up to Day 27 in Part 3

  16. Part 1: Number of Participants Based on Antidrug Antibodies (ADA) Status in Serum

    A 3-tiered ADA testing strategy was used in this study. A sample was initially screened for ADA by the ADA screening assay. Any positive sample in the screening assay was considered a potential positive, which was confirmed for true positivity by the confirmatory assay. If a sample was confirmed as an ADA true positive, ADA titer was assessed. ADA-positive was defined as participants who have confirmed positive ADA status in at least 1 postbaseline assessments. ADA-negative was defined as participants who did not have a confirmed positive ADA status in any postbaseline assessment. For ADA-positive only, high ADA titer was defined as participant who had at least 1 postbaseline ADA titer \>16; low ADA titer was defined as participant whose postbaseline ADA titers were all ≤16 and data is presented accordingly for each of these categories.

    Time frame: Predose on Day 1 and post-dose on Days 14 and 29 in Part 1

  17. Part 2: Number of Participants With ADA

    Time frame: Predose on Day 1 and post-dose on Days 14 and 29 in Part 2

  18. Part 3: Number of Participants With ADA

    Time frame: Predose on Day 1 and post-dose on Days 14 and 29 in Part 3

Other outcomes

  1. Part 1: Cmax: Maximum Observed Plasma Concentration of TAK-951

    Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

  2. Part 1: AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for TAK-951

    Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

    Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 1

  3. Part 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951

    Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

  4. Part 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration for TAK-951

    Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

  5. Part 1: Tmax: Time of First Occurrence of Cmax for TAK-951

    Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

  6. Part 1: t1/2z: Terminal Disposition Phase Half-life for TAK-951

    Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

  7. Part 1: CL/F: Apparent Clearance After Extravascular Administration of TAK-951

    Apparent clearance after extravascular administration was calculated as Dose/AUC∞. Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

  8. Part 1: Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration

    Apparent volume of distribution during the terminal disposition phase after extravascular administration was calculated as (CL/F)/λz, where λz is the terminal elimination rate constant. Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

    Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

07

Results

Posted Nov 22, 2024

Participant flow

Participants took part in the study at 2 investigative sites in the United States from 7 January 2022 to 21 September 2023.

Part 1
Participant flow — Part 1
MilestonePart 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6Part 2, TAK-951 Multiple Rising Dose CohortPart 3, TAK-951 Multiple Dose Titration Cohort
Started1266666600
Completed1266666600
Not completed000000000
Part 2
Participant flow — Part 2
MilestonePart 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6Part 2, TAK-951 Multiple Rising Dose CohortPart 3, TAK-951 Multiple Dose Titration Cohort
Started000000000
Completed000000000
Not completed000000000
Part 3
Participant flow — Part 3
MilestonePart 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6Part 2, TAK-951 Multiple Rising Dose CohortPart 3, TAK-951 Multiple Dose Titration Cohort
Started000000000
Completed000000000
Not completed000000000

Outcome measures

PrimaryPart 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, electrocardiogram (ECG), laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.

Time frame:
From the first dose of study drug up to Day 29 in Part 1
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPart 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)6456546
PrimaryPart 2: Number of Participants With TEAEs

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.

Time frame:
From the first dose of study drug up to Day 33 in Part 2

No measurements were reported for this outcome.

PrimaryPart 3: Number of Participants With TEAEs

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.

Time frame:
From the first dose of study drug up to Day 27 in Part 3

No measurements were reported for this outcome.

Other pre-specifiedPart 1: Cmax: Maximum Observed Plasma Concentration of TAK-951

Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

Results for this outcome have not been posted.

Other pre-specifiedPart 1: AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for TAK-951

Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

Time frame:
Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 1

Results for this outcome have not been posted.

Other pre-specifiedPart 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951

Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

Results for this outcome have not been posted.

Other pre-specifiedPart 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration for TAK-951

Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

Results for this outcome have not been posted.

Other pre-specifiedPart 1: Tmax: Time of First Occurrence of Cmax for TAK-951

Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

Results for this outcome have not been posted.

Other pre-specifiedPart 1: t1/2z: Terminal Disposition Phase Half-life for TAK-951

Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

Results for this outcome have not been posted.

Other pre-specifiedPart 1: CL/F: Apparent Clearance After Extravascular Administration of TAK-951

Apparent clearance after extravascular administration was calculated as Dose/AUC∞. Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

Results for this outcome have not been posted.

Other pre-specifiedPart 1: Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration

Apparent volume of distribution during the terminal disposition phase after extravascular administration was calculated as (CL/F)/λz, where λz is the terminal elimination rate constant. Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1

Results for this outcome have not been posted.

SecondaryPart 2: Maximum Observed Plasma Concentration (Cmax) for TAK-951 on Day 1 of Drug Dosing
Time frame:
Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Time of First Occurrence of Cmax (Tmax) for TAK-951 on Day 1 of Drug Dosing
Time frame:
Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) for TAK-951 on Day 1 of Drug Dosing
Time frame:
Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval for TAK-951 on Day 1

Tau (τ) indicates the length of the dosing interval.

Time frame:
Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: AUCτ for TAK-951 at Steady State

τ indicates the length of the dosing interval.

Time frame:
Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: AUC24 for TAK-951 at Steady State
Time frame:
Predose on Day 1 and at multiple time points post-dose up to 24 hours on Day 1 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Cmax,ss: Maximum Observed Concentration at Steady State for TAK-951
Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Tmax for TAK-951 at Steady State
Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Terminal Disposition Phase Half-life (t1/2z) for TAK-951 at Steady State
Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Apparent Clearance After Extravascular Administration (CL/F) for TAK-951 at Steady State

Apparent clearance after extravascular administration was to be calculated as Dose/AUCτ after multiple dosing.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration (Vz/F) for TAK-951 at Steady State

Apparent volume of distribution during the terminal disposition phase after extravascular administration was to be calculated as (CL/F)/λz at steady state, with λz as the terminal elimination rate constant.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Ctrough: Observed Plasma Concentration at the End of a Dosing Interval for TAK-951 at Steady State
Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Rac[AUC]: Accumulation Ratio Based on AUCτ for TAK-951 at Steady State

Rac\[AUC\] was to be calculated as the ratio of AUCτ at steady state/AUCτ after a single dose.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

No measurements were reported for this outcome.

SecondaryPart 2: Rac[Cmax]: Accumulation Ratio Based on Cmax for TAK-951 at Steady State

Rac\[Cmax\] was to be calculated as the ratio of Cmax at steady state/Cmax after a single dose.

Time frame:
Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2

No measurements were reported for this outcome.

SecondaryPart 3: Number of Participants With AEs

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.

Time frame:
From the re-treatment dose of study drug (any day from Days 8 to 13) up to Day 27 in Part 3

No measurements were reported for this outcome.

SecondaryPart 1: Number of Participants Based on Antidrug Antibodies (ADA) Status in Serum

A 3-tiered ADA testing strategy was used in this study. A sample was initially screened for ADA by the ADA screening assay. Any positive sample in the screening assay was considered a potential positive, which was confirmed for true positivity by the confirmatory assay. If a sample was confirmed as an ADA true positive, ADA titer was assessed. ADA-positive was defined as participants who have confirmed positive ADA status in at least 1 postbaseline assessments. ADA-negative was defined as participants who did not have a confirmed positive ADA status in any postbaseline assessment. For ADA-positive only, high ADA titer was defined as participant who had at least 1 postbaseline ADA titer \>16; low ADA titer was defined as participant whose postbaseline ADA titers were all ≤16 and data is presented accordingly for each of these categories.

Time frame:
Predose on Day 1 and post-dose on Days 14 and 29 in Part 1
Reported as:
Count of participants · Participants
Part 1: Number of Participants Based on Antidrug Antibodies (ADA) Status in Serum
ParticipantsPart 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6
Day 1: Negative12666566
Day 1: Positive: Low Titer0000100
Day 1: Positive: High Titer0000000
Day 14: Negative12666566
Day 14: Positive: Low Titer0000100
Day 14: Positive: High Titer0000000
Day 29: Negative12666566
Day 29: Positive: Low Titer0000100
Day 29: Positive: High Titer0000000
SecondaryPart 2: Number of Participants With ADA
Time frame:
Predose on Day 1 and post-dose on Days 14 and 29 in Part 2

No measurements were reported for this outcome.

SecondaryPart 3: Number of Participants With ADA
Time frame:
Predose on Day 1 and post-dose on Days 14 and 29 in Part 3

No measurements were reported for this outcome.

Adverse events

Collected over From the first dose of study drug up to Day 29 in Part 1. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Pooled Placebo0/12 (0%)0/12 (0%)6/12 (50%)
Part 1, Cohort 1: TAK-951 Dose 10/6 (0%)0/6 (0%)4/6 (66.7%)
Part 1, Cohort 2: TAK-951 Dose 20/6 (0%)0/6 (0%)5/6 (83.3%)
Part 1, Cohort 3: TAK-951 Dose 30/6 (0%)0/6 (0%)6/6 (100%)
Part 1, Cohort 4: TAK-951 Dose 40/6 (0%)1/6 (16.7%)5/6 (83.3%)
Part 1, Cohort 5: TAK-951 Dose 50/6 (0%)0/6 (0%)4/6 (66.7%)
Part 1, Cohort 6: TAK-951 Dose 60/6 (0%)0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPart 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6
SyncopeNervous system disorders0/120/60/60/61/60/60/6
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPart 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6
TachycardiaCardiac disorders2/122/62/65/62/64/65/6
Orthostatic hypotensionVascular disorders0/121/61/61/63/62/60/6
Injection site reactionGeneral disorders0/120/62/62/60/60/60/6
Pain in extremityMusculoskeletal and connective tissue disorders0/120/62/60/60/60/61/6
PresyncopeNervous system disorders0/120/60/62/62/60/60/6
Back painMusculoskeletal and connective tissue disorders0/120/61/60/60/60/60/6
Blood creatine phosphokinase increasedInvestigations0/120/61/60/60/60/60/6
DiarrhoeaGastrointestinal disorders0/120/61/60/60/60/60/6
DizzinessNervous system disorders0/120/60/60/60/60/61/6
Dry mouthGastrointestinal disorders0/120/60/61/60/60/61/6

Baseline characteristics

The Safety Analysis Set included all participants who were randomized and received at least 1 dose of study treatment. This study was terminated after completion of Part 1 following the Sponsor's decision attributed to the benefit-risk profile derived from the Part 1 data. Hence, no participants were enrolled in Parts 2 and 3.

Age, Continuous
Age, Continuous(years)Part 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6Part 2, TAK-951 Multiple Rising Dose CohortPart 3, TAK-951 Multiple Dose Titration CohortTotal
Mean33.36 ± 10.6834.5 ± 10.0735.2 ± 5.9131.7 ± 9.7130.0 ± 8.9228.0 ± 11.1040.2 ± 10.09——33.3 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6Part 2, TAK-951 Multiple Rising Dose CohortPart 3, TAK-951 Multiple Dose Titration CohortTotal
Female21020230010
Male105646430038
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6Part 2, TAK-951 Multiple Rising Dose CohortPart 3, TAK-951 Multiple Dose Titration CohortTotal
Ethnicity — Hispanic or Latino50221120013
Ethnicity — Not Hispanic or Latino76445540035
Ethnicity — Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Pooled PlaceboPart 1, Cohort 1: TAK-951 Dose 1Part 1, Cohort 2: TAK-951 Dose 2Part 1, Cohort 3: TAK-951 Dose 3Part 1, Cohort 4: TAK-951 Dose 4Part 1, Cohort 5: TAK-951 Dose 5Part 1, Cohort 6: TAK-951 Dose 6Part 2, TAK-951 Multiple Rising Dose CohortPart 3, TAK-951 Multiple Dose Titration CohortTotal
Race — American Indian or Alaska Native1000000001
Race — Asian0100000001
Race — Native Hawaiian or Other Pacific Islander0000010001
Race — Black or African American1112000005
Race — White84346560036
Race — More than one race2020000004
Race — Unknown or Not Reported0000000000
08

Study locations

2 sites
  • ICON
    Lenexa, Kansas 66219, United States
  • ICON
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Sep 2023, 20 months.

Results were first posted in Nov 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2024
First posted
Sep 24, 2024
StartActual
Jan 7, 2022
Primary completionActual
Sep 21, 2023
CompletionActual
Sep 21, 2023
Results first posted
Nov 22, 2024
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06610279
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 24, 2024
Start date
Jan 7, 2022
Primary completion
Sep 21, 2023
Completion
Sep 21, 2023
Results posted
Nov 22, 2024
Last update
Nov 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-951

Start the discussion